Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality

被引:21
作者
Matsuo, H
Hayashi, J
Ono, K
Andoh, K
Andoh, Y
Sano, Y
Saruki, K
Tanaka, J
Yamashita, M
Nakamura, K
Kubo, K
机构
[1] HIDAKA HOSP,DEPT SURG,TAKASAKI,GUMMA 370,JAPAN
[2] HIDAKA HOSP,DEPT UROL,TAKASAKI,GUMMA 370,JAPAN
[3] UNIV TSUKUBA,DEPT ACUTE MED,TSUKUBA,IBARAKI 305,JAPAN
[4] TOKYO WOMENS MED COLL,DEPT NEPHROL,TOKYO 162,JAPAN
关键词
D O I
10.1128/AAC.41.12.2597
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We describe a new modality for administering aminoglycosides to hemodialysis (HD) patients, namely, a modification of the once-daily regimen which consists of administering the aminoglycosides over 60 min by drip infusion just before each HD session, with a preplanned peak concentration being reached at the beginning of the session and then with a rapidly decreasing concentration being achieved by the start of HD. The area under the concentration-time curve (AUG), i.e., the accumulation of the drug in the body, is thus minimized by this modality. Arbekacin (ABK) was given at a dose of 2 mg/kg of body weight to 10 HD patients infected with methicillin-resistant Staphylococcus aureus (MRSA) for 2 seeks (six sessions in total), resulting in the complete disappearance of MRSA in 5 patients, A high rate of elimination of ABK was attained for each patient while the patient was on HD (range, 0.20 to 0.42 h(-1); mean 0.28 +/- 0.08 h(-1)) by using high-performance dialyzers provided with membranes made of either polymethylmethacrylate, cellulose triacetate (CTA), or ethylene vinyl alcohol. The best results were obtained with the CTA membrane, as revealed by the overall mass transfer coefficient (K-0), The AUC in the simulation model for the variation in the serum ABK concentration in this modality was calculated to be 40% of that of the conventional post-HD dosing modality, suggesting that a much higher dose could be administered to HD patients who receive HD thrice weekly (4 h per session), giving, e.g., 4 mg/kg initially and before the ED sessions, when there is an interval of 68 h from HD session to HD session, and giving 2 mg/kg before the other sessions.
引用
收藏
页码:2597 / 2601
页数:5
相关论文
共 14 条
[1]   GENTAMICIN CLEARANCE DURING HEMODIALYSIS - A COMPARISON OF HIGH-EFFICIENCY CUPRAMMONIUM RAYON AND CONVENTIONAL CELLULOSE ESTER HEMODIALYZERS [J].
AGARWAL, R ;
TOTO, RD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (02) :296-299
[2]  
Aoki Yasuko, 1994, Japanese Journal of Antibiotics, V47, P640
[3]   A SUGGESTED APPROACH TO ONCE-DAILY AMINOGLYCOSIDE DOSING [J].
BEGG, EJ ;
BARCLAY, ML ;
DUFFULL, SB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (06) :605-609
[4]  
COREA AL, 1993, DIALYSIS THERAPY, P93
[5]   PHARMACOKINETICS OF HABEKACIN IN PATIENTS WITH RENAL-INSUFFICIENCY [J].
FILLASTRE, JP ;
LEROY, A ;
HUMBERT, G ;
MOULIN, B ;
BERNADET, P ;
JOSSE, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :575-577
[6]  
Gilbert D N, 1989, Infect Dis Clin North Am, V3, P517
[7]   ONCE-DAILY AMINOGLYCOSIDE THERAPY [J].
GILBERT, DN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :399-405
[8]   ACTIVITY OF THE SEMISYNTHETIC KANAMYCIN-B DERIVATIVE, ARBEKACIN AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
HAMILTONMILLER, JMT ;
SHAH, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (06) :865-868
[9]  
HAYASHI I, 1994, DRUG EXP CLIN RES, V20, P225
[10]  
KAUPUSNIK JE, 1986, J ANTIMICROB CHEM SA, V17, P7